**Cyclosporine before Coronary Artery Bypass Grafting does not prevent postoperative decreases in renal function: A randomized clinical trial.**

Per Ederoth M.D. Ph.D1, Alain Dardashti M.D. Ph.D1, Edgars Grins M.D.1, Björn Brondén M.D. Ph.D1, Carsten Metzsch M.D.Ph.D1, André Erdling M.D.1, Shahab Nozohoor M.D. Ph.D2, Arash Mokhtari M.D. Ph.D2, Magnus J. Hansson M.D. Ph.D3, Eskil Elmér M.D. Ph.D3, Lars Algotsson M.D. Ph.D1, Stefan Jovinge M.D. Ph.D4, Henrik Bjursten M.D. Ph.D.2

1Department of Anesthesiology and Intensive Care, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden

2Department of Cardiothoracic Surgery, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden

3Department of Mitochondrial Medicine, Clinical Sciences, Lund University, Lund, Sweden

4Fredrik Meijer Heart and Vascular Institute Spectrum Health, MI US. Van Andel Institute, Grand Rapids, MI US Cardiovascular Institute, Stanford University CA US

Corresponding author:
henrik.bjursten@med.lu.se

Supplementary Appendix CiPRICS Trial

Table of Contents

[Table S1. Markers of myocardial damage 3](#_Toc503526552)

[Table S2. Marker of cerebral damage 4](#_Toc503526553)

[Table S3. SAE listing according MedRa classification 5](#_Toc503526554)

[Table S4. Safety biochemistry. 6](#_Toc503526555)

[Table S5. Diuretics 9](#_Toc503526556)

## Table S1. Markers of myocardial damage

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Markers of myocardial damage** | **Placebo (N=79)** | **Cyclosporine (N=75)** | **p** |  |
|  |  |  |  |  |  |
| Plasma Troponin T (ng/L) |  |  | 0.279\* |  |
|  Day -1 | 43 ± 123 | 35 ± 126 |  |  |
|  4 hours | 381 ± 202  | 334 ± 164  |  |  |
|  8 hours | 390 ± 184  | 366 ± 204  |  |  |
|  12 hours | 332 ± 176  | 361 ± 331  |  |  |
|  24 hours | 269 ± 189  | 286 ± 294  |  |  |
|  Day 2 | 251 ± 223  | 330 ± 900  |  |  |
|  Day 3 | 222 ± 213  | 327 ± 1153  |  |  |
|  Day 4 | 221 ± 271  | 313 ± 1094  |  |  |
|  |  |  |  |  |
| Plasma CK-MB (µg/L) |  |  | 0.412\* |  |
|  Day -1 | 2.7 ± 1.7 | 2.81 ± 3.0 |  |  |
|  4 hours | 14.9 ± 6.0 | 14.6 ± 5.4  |  |  |
|  8 hours | 15.5 ± 9.4  | 15.7 ± 9.9  |  |  |
|  12 hours | 15.7 ± 15.8  | 16.1 ± 15.9  |  |  |
|  24 hours | 14.4 ± 18.1  | 14.0 ± 21.1  |  |  |
|  Day 2 | 6.8 ± 8.2  | 7.3 ± 17.3  |  |  |
|  Day 3 | 3.2 ± 2.7  | 3.6 ± 8.0  |  |  |
|  Day 4 | 2.6 ± 2.3  | 2.3 ± 2.3  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| CK-MB AUC (µg\*h/L) | 780.9 ± 667.3 | 793.3 ± 1137.6 | 0.699\*\* |  |
|  |  |  |  |  |
| Troponin-T AUC (ng\*h/L) | 24614 ± 18030 | 30377 ± 68508 | 0.206\*\* |  |

Table S1. Markers of myocardial damage expressed as mean ± SD. Day -1 illustrates the day before surgery, usually the same as admission day. Day 0 surgery day, Day 1 the day after surgery etc. Hours means hours after study drug administration. \*Testing with Linear Mixed Model. **T**roponin and CK-MB log transformed before testing.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Marker of cerebral damage** | **Placebo (N=79)** | **Cyclosporine (N=75)** | **p** |  |
|  |  |  |  |  |
| Serum S100B (µg/L) |  |  | 0.677\* |  |
|  Day -1 | 0.07 ± 0.08 | 0.06 ± 0.03 |  |  |
|  Day 1 | 0.16 ± 0.17 | 0.16 ± 0.07 |  |  |
|  Day 2 | 0.14 ± 0.15 | 0.13 ± 0.06 |  |  |

## Table S2. Marker of cerebral damage

Table S2. Marker of cerebral damage expressed as mean ± SD. Day -1 illustrates the day before surgery, usually the same as admission day. Day 0 surgery day, Day 1 the day after surgery etc. \*Testing with Linear Mixed Model. S100B log transformed before testing.

## Table S3. SAE listing according MedRa classification

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Placebo | Cyclosporine |
|  |  | n (%) | n (%) |
|  SAE  | 14 (53.8) | 12 (46.2) |
|  | Postoperative wound infection | 0 (0.00) | 1 (8.33) |
|  | Atrial fibrillation | 0 (0.00) | 1 (8.33) |
|  | Cardiac arrest, Myocardial infarction, Pulmonary oedema | 1 (7.14) | 0 (0.00) |
|  | Cardiac disorder | 1 (7.14) | 0 (0.00) |
|  | Cardiac failure | 0 (0.00) | 1 (8.33) |
|  | Chest pain, Nausea, Vomiting | 1 (7.14) | 0 (0.00) |
|  | Colon gangrene | 0 (0.00) | 1 (8.33) |
|  | Deep vein thrombosis | 1 (7.14) | 0 (0.00) |
|  | Gastrointestinal bleeding | 1 (7.14) | 0 (0.00) |
|  | Gastrointestinal bleeding, Cardiac arrest | 0 (0.00) | 1 (8.33) |
|  | Hydronephrosis, Ureteral stricture | 1 (7.14) | 0 (0.00) |
|  | Infection | 1 (7.14) | 0 (0.00) |
|  | Mediastinitis | 1 (7.14) | 0 (0.00) |
|  | Non-cardiac chest pain | 1 (7.14) | 0 (0.00) |
|  | Pericardial effusion | 1 (7.14) | 1 (8.33) |
|  | Pleural effusion | 0 (0.00) | 3 (25.00) |
|  | Pneumonia | 1 (7.14) | 1 (8.33) |
|  | Postpericardiotomy syndrome | 1 (7.14) | 0 (0.00) |
|  | Raised liver function tests | 0 (0.00) | 1 (8.33) |
|  | Stroke | 2 (14.29) | 0 (0.00) |
|  | Vascular graft occlusion, myocardial infarction | 0 (0.00) | 1 (8.33) |

Table S3. SAE listing according MedRa classification

## Table S4. Safety biochemistry.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Safety Chemistry** | **Placebo (N=79)** | **Cyclosporine (N=75)** | **p** |  |
|  |  |  |  |  |  |
| Plasma Potassium (mmol/L) |  |  | 0.007\* |  |
|  Preoperatively | 4.1 ± 0.3 | 4.1 ± 0.3 |  |  |
|  Day 1 | 4.5 ± 0.3 | 4.6 ± 0.3 | 0.290\* |  |
|  Day 2 | 4.1 ± 0.4 | 4.3 ± 0.3 | <0.001\* |  |
|  Day 3 | 4.1 ± 0.3 | 4.1 ± 0.3 | 0.978\* |  |
|  Day 4 | 4.2 ± 0.4 | 4.2 ± 0.4 | 0.867\* |  |
|  |  |  |  |  |
| Plasma Mg (mmol/L) |  |  | 0.696\* |  |
|  Preoperatively | 0.8 ± 0.1 | 0.8 ± 0.1 |  |  |
|  Day 1 | 1.1 ± 0.2 | 1.1 ± 0.2 |  |  |
|  Day 2 | 0.9 ± 0.1 | 0.9 ± 0.2 |  |  |
|  Day 3 | 0.9 ± 0.1 | 0.9 ± 0.3 |  |  |
|  Day 4 | 0.9 ± 0.1 | 0.9 ± 0.2 |  |  |
|  |  |  |  |  |
| Plasma CK (µkat/L) |  |  | 0.635\* |  |
|  Preoperatively | 1.7 ± 1.2 | 1.7 ± 1.3 |  |  |
|  Day 1 | 10.3 ± 6.5 | 9.1 ± 6.3 |  |  |
|  Day 2 | 11.8 ± 11.7 | 10.7 ± 9.8 |  |  |
|  Day 3 | 8.1 ± 9.1 | 7.6 ± 9.1 |  |  |
|  Day 4 | 4.6 ± 4.7 | 4.6 ± 5.0 |  |  |
|  |  |  |  |  |
| Plasma Bilirubin (µmol/L) |  |  | 0.933\* |  |
|  Preoperatively | 8.4 ± 4.3 | 7.6 ± 3.8 |  |  |
|  Day 1 | 12.2 ± 5.3 | 13.5 ± 7.0 |  |  |
|  Day 2 | 11.0 ± 4.7 | 12.7 ± 8.0 |  |  |
|  Day 3 | 9.8 ± 4.9 | 11.1 ± 6.6 |  |  |
|  Day 4 | 9.9 ± 5.1 | 10.8 ± 5.6 |  |  |
|  |  |  |  |  |
| Plasma ASAT (µkat/L) |  |  | 0.722\* |  |
|  Preoperatively | 0.5 ± 0.3 | 0.7 ± 0.4 |  |  |
|  Day 1 | 0.8 ± 0.4 | 0.9 ± 0.8 |  |  |
|  Day 2 | 0.7 ± 0.4 | 1.0 ± 3.3 |  |  |
|  Day 3 | 0.6 ± 0.3 | 1.3 ± 6.1 |  |  |
|  Day 4 | 0.7 ± 1.0 | 0.9 ± 2.7 |  |  |
|  |  |  |  |  |
| P-ALAT (µkat/L) |  |  | 0.532\* |  |
|  Preoperatively | 0.7 ± 0.5 | 1.0 ± 1.0 |  |  |
|  Day 1 | 0.6 ± 0.6 | 0.9 ± 0.8 |  |  |
|  Day 2 | 0.5 ± 0.4 | 1.1 ± 3.8 |  |  |
|  Day 3 | 0.5 ± 0.3 | 1.3 ± 5.9 |  |  |
|  Day 4 | 0.7 ± 1.3 | 1.1 ± 4.5 |  |  |
|  |  |  |  |  |
| Plasma GT (µkat/L) |  |  | 0.856\* |  |
|  Preoperatively | 1.2 ± 2.1 | 0.9 ± 0.9 |  |  |
|  Day 1 | 0.9 ± 1.4 | 0.7 ± 0.7 |  |  |
|  Day 2 | 0.8 ± 1.3 | 0.7 ± 0.6 |  |  |
|  Day 3 | 1.0 ± 1.5 | 0.8 ± 0.8 |  |  |
|  Day 4 | 1.3 ± 1.7 | 1.0 ± 1.1 |  |  |
|  |  |  |  |  |
| P-ALP (µkat/L) |  |  | 0.824\* |  |
|  Preoperatively | 1.4 ± 0.7 | 1.4 ± 0.6 |  |  |
|  Day 1 | 1.0 ± 0.4 | 1.0 ± 0.5 |  |  |
|  Day 2 | 1.0 ± 0.4 | 1.1 ± 0.4 |  |  |
|  Day 3 | 1.1 ± 0.5 | 1.2 ± 0.7 |  |  |
|  Day 4 | 1.3 ± 0.9 | 1.5 ± 1.2 |  |  |
|  |  |  |  |  |
| Plasma CRP (mg/L) |  |  | <0.001\* |  |
|  Preoperatively | 6.1 ± 9.0 | 4.0 ± 6.1 |  |  |
|  Day 1 | 63.4 ± 27.8 | 59.0 ± 33.0 | 0.286 |  |
|  Day 2 | 171.8 ± 67.9 | 196.7 ± 75.5 | 0.002 |  |
|  Day 3 | 185.5 ± 73.2 | 223.7 ± 82.9 | <0.001 |  |
|  Day 4 | 141.2 ± 73.6 | 175.4 ± 74.2 | <0.001 |  |
|  |  |  |  |  |
| Blood Leukocytes (109/L) |  |  | 0.032\* |  |
|  Preoperatively | 7.7 ± 1.8 | 7.5 ± 1.7 |  |  |
|  Day 1 | 11.8 ± 3.5  | 13.5 ± 3.5 | <0.001 |  |
|  Day 2 | 11.8 ± 2.8  | 13.5 ± 3.3  | <0.001 |  |
|  Day 3 | 11.1 ± 2.7 | 12.0 ± 2.5  | 0.002 |  |
|  Day 4 | 9.7 ± 2.5  | 10.1 ± 2.2  | 0.033 |  |
|  |  |  |  |  |
| Blood Haemoglobin (g/L) |  |  | 0.046\* |  |
|  Preoperatively | 137.8 ± 15.8 | 135.6 ± 13.7 |  |  |
|  Day 1 | 111.8 ± 13.1 | 108.9 ± 12.4 | 0.326 |  |
|  Day 2 | 103.2 ± 12.8 | 101.8 ± 11.4 | 0.826 |  |
|  Day 3 | 104.1 ± 11.9 | 99.1 ± 11.1 | 0.023 |  |
|  Day 4 | 105.7 ± 12.4 | 101.5 ± 10.9 | 0.064 |  |
|  |  |  |  |  |
| Blood Thrombocytes (109/L) |  |  | 0.019\* |  |
|  Preoperatively | 237.5 ± 60.6 | 242.3 ± 63.2 |  |  |
|  Day 1 | 186.0 ± 47.0 | 187.5 ± 53.0 | 0.979 |  |
|  Day 2 | 169.3 ± 46.0 | 164.9 ± 44.3 | 0.108 |  |
|  Day 3 | 183.2 ± 47.8 | 173.5 ± 47.5 | 0.012 |  |
|  Day 4 | 225.2 ± 56.8 | 210.4 ± 55.1 | 0.006 |  |
|  |  |  |  |  |

Table S4. Safety biochemistry expressed as mean ± SD. Outcome in terms of safety related clinical chemistry. Day -1 illustrates the day before surgery, usually the same as admission day. Day 0 surgery day, Day 1 the day after surgery etc. Mg = Magnesium, ASAT = Aspartate Aminotransferase, ALAT = Alanine Aminotransferase, ALP = Alkaline Phosphatase, GT = Gamma-glutamyl Transferase, CRP = C-Reactive Protein, CK = Creatine Kinase. \* Linear Mixed Model. All variables (besides potassium and haemoglobin) log transformed before testing.

## Table S5. Diuretics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Diuretics** | **Placebo (N=79)** | **Cyclosporine (N=75)** | **p** |  |
|  |  |  |  |  |  |
| Furosemide (mg) |  |  |  |  |
|  Day 0 | 0 (0‒0) | 0 (0‒10) | 0.185 |  |
|  Day 1 | 85 (60‒120) | 100 (80‒133) | 0.077 |  |
|  Day 2 | 80 (40‒90) | 80 (80‒120) | 0.002 |  |
|  Day 3 | 40 (0‒80) | 80 (40‒80) | 0.007 |  |
|  Day 4 | 20 (0‒40) | 40 (0‒80) | 0.053 |  |
|  |  |  |  |  |
| Amilorid (mg) |  |  |  |  |
|  Day 0 | 0 (0‒0)  | 0 (0‒0) | 0.970  |  |
|  Day 1 | 5 (0‒5)  | 5 (5‒5)  | 0.203 |  |
|  Day 2 | 5 (0‒5)  | 5 (0‒5)  | 0.242 |  |
|  Day 3 | 0 (0‒5)  | 5 (0‒5)  | 0.004 |  |
|  Day 4 | 0 (0‒5) | 5 (0‒5)  | 0.011  |  |
|  |  |  |  |  |

Table S5: Administration of diuretics (intravenous and orally combined) in the two groups. Median (IQR). All testing with Mann-Whitney U-test.